Drs. Ruben P.A. van Eijk and Jordi van Unnik discuss the planning of interim analyses for clinical trials in ALS to maximize patient safety and minimize exposure to ineffective or harmful drugs.
Show references: https://n.neurology.org/content/100/23/e2398
